FDA OKs Crisaborole for Use in Children as Young as 3 Months of Age
March 24, 2020
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
Atopic Dermatitis
Abrocitinib Improves Moderate-to-Severe Atopic Dermatitis in Phase 3 Study
March 23, 2020
Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.
New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis
February 4, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
FDA Grants Priority Review to Dupilumab for Children with Atopic Dermatitis
January 28, 2020
If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.
